Cargando…
Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis
Asherman's Syndrome (AS) is an uncommon, acquired, and refractory gynecological disorder. Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. Here, we conducted a meta-analysis of self-controlled clinical trials to assess...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769648/ https://www.ncbi.nlm.nih.gov/pubmed/33414830 http://dx.doi.org/10.1155/2020/8820538 |
_version_ | 1783629371967275008 |
---|---|
author | Zhao, Yiming Luo, Qifan Zhang, Xiao Qin, Yafei Hao, Jingpeng Kong, Dejun Wang, Hongda Li, Guangming Gu, Xiangying Wang, Hao |
author_facet | Zhao, Yiming Luo, Qifan Zhang, Xiao Qin, Yafei Hao, Jingpeng Kong, Dejun Wang, Hongda Li, Guangming Gu, Xiangying Wang, Hao |
author_sort | Zhao, Yiming |
collection | PubMed |
description | Asherman's Syndrome (AS) is an uncommon, acquired, and refractory gynecological disorder. Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. Here, we conducted a meta-analysis of self-controlled clinical trials to assess the effectiveness and safety of stem cell-based therapy in Asherman syndrome patients who have failed in conventional treatment. We systematically searched PubMed, Embase, Cochrane, and Web of Science database (published up to October 3, 2020). Our main evaluation outcomes were menses improvement, endometrial thickness changes, pregnancy outcome, and side effects. All analyses were performed by using RevMan5.4 software. 427 studies were identified, eight of which were eligible and included in our analysis. Stem cell combined hormone therapy achieved a higher likelihood of improving menstruation (risk ratio [RR] 22.43, 95% CI: 8.03 to 62.68, P < 0.00001), an enhancement of pregnancy outcome (risk ratio [RR] 11.1, 95% CI: 3.58 to 34.38, P < 0.0001), and a mean increase of 3-month endometrial thickness (standardized mean difference [SMD] 2.43, 95% CI: 1.72 to 3.13, P < 0.00001). Subgroup analysis also indicated that 6-month and 9-month endometrial thickness increased significantly with the stem cell-based treatment. Moreover, no obvious and severe adverse reactions were observed during the process of stem cell therapy. There were 3 patients (3.57%) reported with lost appetite, mild gastritis, vomiting, or abdominal cramps, whereas, these symptoms relieved subsequently. This meta-analysis systematically reviewed and synthesized the outcomes of stem cell-based therapy in treating Asherman syndrome, which suggest that stem cell and hormone combination therapy was safe and more effective in improving menstruation duration, pregnancy outcome, and endometrial thickness. However, further trials with large sample sizes are needed to establish more solid evidence for administrating this therapy in clinic. |
format | Online Article Text |
id | pubmed-7769648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-77696482021-01-06 Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis Zhao, Yiming Luo, Qifan Zhang, Xiao Qin, Yafei Hao, Jingpeng Kong, Dejun Wang, Hongda Li, Guangming Gu, Xiangying Wang, Hao Stem Cells Int Research Article Asherman's Syndrome (AS) is an uncommon, acquired, and refractory gynecological disorder. Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. Here, we conducted a meta-analysis of self-controlled clinical trials to assess the effectiveness and safety of stem cell-based therapy in Asherman syndrome patients who have failed in conventional treatment. We systematically searched PubMed, Embase, Cochrane, and Web of Science database (published up to October 3, 2020). Our main evaluation outcomes were menses improvement, endometrial thickness changes, pregnancy outcome, and side effects. All analyses were performed by using RevMan5.4 software. 427 studies were identified, eight of which were eligible and included in our analysis. Stem cell combined hormone therapy achieved a higher likelihood of improving menstruation (risk ratio [RR] 22.43, 95% CI: 8.03 to 62.68, P < 0.00001), an enhancement of pregnancy outcome (risk ratio [RR] 11.1, 95% CI: 3.58 to 34.38, P < 0.0001), and a mean increase of 3-month endometrial thickness (standardized mean difference [SMD] 2.43, 95% CI: 1.72 to 3.13, P < 0.00001). Subgroup analysis also indicated that 6-month and 9-month endometrial thickness increased significantly with the stem cell-based treatment. Moreover, no obvious and severe adverse reactions were observed during the process of stem cell therapy. There were 3 patients (3.57%) reported with lost appetite, mild gastritis, vomiting, or abdominal cramps, whereas, these symptoms relieved subsequently. This meta-analysis systematically reviewed and synthesized the outcomes of stem cell-based therapy in treating Asherman syndrome, which suggest that stem cell and hormone combination therapy was safe and more effective in improving menstruation duration, pregnancy outcome, and endometrial thickness. However, further trials with large sample sizes are needed to establish more solid evidence for administrating this therapy in clinic. Hindawi 2020-12-19 /pmc/articles/PMC7769648/ /pubmed/33414830 http://dx.doi.org/10.1155/2020/8820538 Text en Copyright © 2020 Yiming Zhao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhao, Yiming Luo, Qifan Zhang, Xiao Qin, Yafei Hao, Jingpeng Kong, Dejun Wang, Hongda Li, Guangming Gu, Xiangying Wang, Hao Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
title | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
title_full | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
title_fullStr | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
title_full_unstemmed | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
title_short | Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis |
title_sort | clinical efficacy and safety of stem cell-based therapy in treating asherman syndrome: a system review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769648/ https://www.ncbi.nlm.nih.gov/pubmed/33414830 http://dx.doi.org/10.1155/2020/8820538 |
work_keys_str_mv | AT zhaoyiming clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT luoqifan clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT zhangxiao clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT qinyafei clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT haojingpeng clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT kongdejun clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT wanghongda clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT liguangming clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT guxiangying clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis AT wanghao clinicalefficacyandsafetyofstemcellbasedtherapyintreatingashermansyndromeasystemreviewandmetaanalysis |